The UK competition authority, Competition and Markets Authority (CMA) has appealed the Court’s decision that annulled CMA’s fining decision against drug companies’ pay for delay arrangements.
CMA found that GlaxoSmithKline paid over 50 million Pounds to generic suppliers of paroxetine for delaying their market entry to UK. The authority also found that paroxetine price decreased by 70% within 2 years after the release of the entry of these suppliers to UK.
The CMA insisted on its 45 million pound fine against GlaxoSmithKline and other pharmaceutical companies that engaged into “pay for delay” agreements and appealed the court decision.